Looking at top Wall Street opinions, Lamb Weston Holdings, Inc. (NYSE: LW) has recently made its way into the research list of BofA/Merrill – signaling that their analyst’s rating adjustment is noteworthy. This stock was upgraded to a rating of Buy in the eyes of BofA/Merrill, whereas its previous rating was Neutral in the eyes of BofA/Merrill, as reported on Tuesday, May 7th, 2019. Another heavy-hitting research note was published by Consumer Edge Research on Friday March 22nd, 2019, with this firm Initiated LW to an updated rating of Outperform. In the past six months and three months of trading, shares of Lamb Weston Holdings, Inc. (LW) have moved by -18.23% and -2.17%, respectively.

Brokerage Updates Related to Lamb Weston Holdings, Inc. (LW) Stock

This publicly-traded organization generated losses of -1.80% over the last 5 sessions. Right now, this stock is the subject of 6 analysts’ evaluations, who – on average – have given this company’s shares a Strong Buy rating. Not a Single analyst have given underperform rating or sell rating, and 3 have given a rating of Buy or better. Based on the 6 stock market experts following this company, the average 12-month price target is $83.17. Moreover, individual price targets range between $76.00-$88.00. With its recent move to $83.00, we can see that these firms project this stock will loss by -0.81% in one year.

Updates from Lamb Weston Holdings, Inc. (LW) SEC Form 4

This particular company’s shares have garnered a lot of attention in recent days, as insiders are unloading their holdings while having generated a 0.10% rise since the beginning of the calendar year.

Lamb Weston Holdings, Inc. (NYSE:LW) Results in the Pipeline

The next scheduled release of financial results for Lamb Weston Holdings, Inc. will be for the Feb-19 quarter. As it stands right now, market analysts are anticipating the per-share earnings for the three-month period will be $0.82. In the same vein, they expect sales for the quarter to amount to $895.04 million.

Now let’s turn to earnings surprise history: in the most recent quarter, the company reported about $926.80 million in revenue alongside EPS at $0.95. On average, the analyst projection was calling for $911.40 million with $0.80 per share in earnings, respectively. In the preceding quarter, this company’s revenue reached $914.90 million, with earnings per share ending up at $0.73.

BioScrip, Inc. (NASDAQ:BIOS) experienced a gain of 4.52% from the closing price in the previous trading day. That boost the price to $2.08 per share, as observed on December 31st, 1969, at a time when the total trading volume reached 2,212,627 shares of stock – compared to the typical average of 1.66M shares per day (as recorded over the past three months). The consensus estimate for these shares has been shifted to $3.79.

Pricing Indications for BioScrip, Inc. (BIOS)

This organization has had a price-to-earnings ratio of in the last year. Meanwhile, it gained 2.15 from its observable 50-day simple moving average. Right at this moment, the per-share value is -30.36% lower than the mean per-share price over the last 200 days in the market.

BioScrip, Inc. (NASDAQ:BIOS) In-Depth Brokerage Insights

We can see that a number of brokerage firms are putting their focus onto this stock. Out of this group, 0 have a sell rating, 2 have a Buy rating, 4 have an outperform rating, while 1 provided a Hold rating for these shares – thanks to data from Thomson Reuters I/B/E/S. Additionally, 0 have recommended that these shares are an Underperforming investment. The current consensus recommendation is at 1.70 , based on information from Thomson Reuters.

BIOS Stock Value Potential

In trading activity as of late, this stock’s value was 2.98 up from its 200 day moving average, while also -4.39% down when compared against its 50-day simple moving average. Over the course of the past year of trading, the share price stuck in the range of $3.25-$4.50. The market value for the entire organization reached 271.86M. In the last trading session, the price ended the day at $1.99. The institutional holdings related to this organization account for 0.60%, and the Beta factor is now 0.58. This company’s RSI (Relative Strength Index) managed to hit 55.11.

BioScrip, Inc. (NASDAQ:BIOS) Analyst Points of Focus

BioScrip, Inc. (BIOS) has found itself inside of Canaccord Genuity’s research list, so their analyst rating adjustment is worth taking note of. This stock was Reiterated to Buy, by Canaccord Genuity, as garnered from a news report on Monday March 18th, 2019. An additional helpful research note was sent out by Stephens’s on Monday March 18th, 2019. The brokerage decided to downgrade BIOS to Equal-Weight from its previous rating of Overweight.